UK markets close in 5 hours 31 minutes

Sanofi (SNY)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
37.22-0.03 (-0.08%)
At close: 04:00PM EDT
37.80 +0.58 (+1.56%)
Pre-market: 05:32AM EDT
Full screen
Trade prices are not sourced from all markets
Previous close37.25
Open37.47
Bid0.00 x 1100
Ask0.00 x 1400
Day's range37.07 - 37.65
52-week range36.91 - 58.10
Volume6,158,343
Avg. volume3,009,274
Market cap94.215B
Beta (5Y monthly)0.42
PE ratio (TTM)14.32
EPS (TTM)2.60
Earnings dateN/A
Forward dividend & yield1.75 (4.55%)
Ex-dividend date26 May 2022
1y target est60.17
  • Reuters

    French drugmaker Sanofi expects positive boost from currency markets in Q3

    PARIS (Reuters) -French drugmaker Sanofi said it expected a positive boost to its third-quarter business results from movements on the currency markets, helped by the strength of the U.S. dollar since Sanofi does much of its business in the United States. Sanofi said its preliminary estimate of currency impacts on its third-quarter 2022 sales was for a boost of approximately 10% to 11%, and for a lift of around 12% and 13% on its business earnings per share (EPS). Sanofi will report third-quarter results on Oct. 28.

  • Globe Newswire

    Press Release: Availability of the Q3 2022 Memorandum for modelling purposes

    Availability of the Q3 2022 Memorandum for modelling purposes Paris, France – September 28, 2022 - Sanofi announced today that its Q3 2022 Memorandum for modelling purposes is available on the "Investors" page of the company's website: https://www.sanofi.com/en/investors/financial-results-and-events/financial-results/Q3-results-2022 As for each quarter, Sanofi prepared this document to assist in the financial modelling of the Group's quarterly results. This document includes a reminder on variou

  • Zacks

    Eli Lilly (LLY) Gets FDA Nod for RET Inhibitor in Solid Tumors

    The FDA grants approval to Lilly's (LLY) Retevmo in advanced or metastatic solid tumors with a RET gene fusion. It converts the drug's accelerated approval in NSCLC indication to full approval.